Jaguar Health Files 8-K on Security Holder Rights

TL;DR

Jaguar Health 8-K filed: Changes to security holder rights and corporate docs. Watch for impacts.

AI Summary

On March 18, 2025, Jaguar Health, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles of incorporation or bylaws. The filing also includes Regulation FD disclosures and financial statements/exhibits, indicating potential changes in corporate structure or security holder agreements.

Why It Matters

This filing signals potential changes to how Jaguar Health's securities are structured or how security holders' rights are defined, which could impact investors and the company's governance.

Risk Assessment

Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate documents can introduce uncertainty and potential shifts in control or value.

Key Numbers

• 001-36714 — Commission File Number (Identifies the company's SEC filing history.)
• 46-2956775 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• March 18, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 200 Pine Street Suite 400 (address) — Principal Executive Offices
• San Francisco, California (location) — Principal Executive Offices City/State
• Jaguar Animal Health, Inc. (company) — Former Company Name

FAQ

From the Filing

0000950170-25-040784.txt : 20250318 0000950170-25-040784.hdr.sgml : 20250318 20250318083009 ACCESSION NUMBER: 0000950170-25-040784 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250318 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250318 DATE AS OF CHANGE: 20250318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25746566 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 jagx-20250318.htm 8-K 8-K false 0001585608 --12-31 0001585608 2025-03-18 2025-03-18   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           200 Pine Street Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 371-8300     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.   Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously disclosed, at the special meeting of stockholders of Jaguar Health, Inc. (the “Company”) held